相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
Yayan T. Sundara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials
Sabine Stegmaier et al.
PEDIATRIC BLOOD & CANCER (2017)
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma
Theodore S. Nowicki et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
Kunio Iura et al.
HUMAN PATHOLOGY (2017)
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer
Xiaomei Gong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
Michael Merker et al.
ONCOTARGET (2017)
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma
Jan Budczies et al.
ONCOIMMUNOLOGY (2017)
The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO
Giada Mondanelli et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
Sapna P. Patel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
Jochen Buechner et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study
Eytan Ben-Ami et al.
CANCER (2017)
T-Cell Infiltration and Clonality Correlate With Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Expression in Patients With Soft Tissue Sarcomas
Seth M. Pollack et al.
CANCER (2017)
The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities
Jonathan Noujaim et al.
BRITISH JOURNAL OF CANCER (2017)
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Melinda S. Merchant et al.
CLINICAL CANCER RESEARCH (2016)
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors
Maximilian Stahl et al.
IMMUNOTHERAPY (2016)
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap et al.
LANCET (2016)
Computational genomics tools for dissecting tumour-immune cell interactions
Hubert Hackl et al.
NATURE REVIEWS GENETICS (2016)
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma
Atilla Engin et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Pratistha Koirala et al.
SCIENTIFIC REPORTS (2016)
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
L. Paoluzzi et al.
CLINICAL SARCOMA RESEARCH (2016)
Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group
Axel Le Cesne et al.
EUROPEAN JOURNAL OF CANCER (2015)
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P. D'Angelo et al.
HUMAN PATHOLOGY (2015)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immunotherapy in Sarcoma: Future Horizons
Melissa Burgess et al.
CURRENT ONCOLOGY REPORTS (2015)
PDGF upregulates CLEC-2 to induce T regulatory cells
Sudhanshu Agrawal et al.
ONCOTARGET (2015)
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Morten F. Gjerstorff et al.
ONCOTARGET (2015)
Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
Nicolas van Baren et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
Debbie M. Ferns et al.
ONCOIMMUNOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma
Tim D. Pencavel et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Parag P. Patwardhan et al.
CLINICAL CANCER RESEARCH (2014)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
Vinit Kumar et al.
IMMUNOLOGY (2014)
A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma
Nitin Patil et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Jonathan Fallon et al.
ONCOTARGET (2014)
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Jacson K. Shen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells
Seth M. Pollack et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Christopher A. Barker et al.
CANCER IMMUNOLOGY RESEARCH (2013)
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M. Pollack et al.
CANCER (2012)
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma
Renske A. de Jong et al.
GYNECOLOGIC ONCOLOGY (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas
Sveinung W. Sorbye et al.
PLOS ONE (2011)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Review of mifamurtide in the treatment of patients with osteosarcoma
Leo Kager et al.
Therapeutics and Clinical Risk Management (2010)
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Hiroshi Urakawa et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma - A retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute between 1986 and 2006
Jacob A. Klapper et al.
CANCER (2008)
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
Crystal L. Mackall et al.
CLINICAL CANCER RESEARCH (2008)
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy
Katie Twigger et al.
CLINICAL CANCER RESEARCH (2008)
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
Jessica B. Katz et al.
IMMUNOLOGICAL REVIEWS (2008)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma
Dennis Hoffmann et al.
HUMAN GENE THERAPY (2007)
Reversal of the TCR stop signal by CTLA-4
Helga Schneider et al.
SCIENCE (2006)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
W Schwinger et al.
ANNALS OF ONCOLOGY (2005)
Interferon-α as the only adjuvant treatment in high-grade osteosarcoma:: Long term results of the Karolinska Hospital series
CR Müller et al.
ACTA ONCOLOGICA (2005)
Cellular and genetic mechanisms of self tolerance and autoimmunity
CC Goodnow et al.
NATURE (2005)
Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production
P Allavena et al.
CANCER RESEARCH (2005)
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
E Galanis et al.
GENE THERAPY (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
A Yovine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Identification of novel survivin-derived CTL epitopes
S Reker et al.
CANCER BIOLOGY & THERAPY (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma
PG Nuciforo et al.
HUMAN PATHOLOGY (2003)
Immunomic analysis of human sarcoma
SY Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses
NS Bharatan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
